Peak Processing Limited: peers
Peak Processing Limited beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Peak Processing Limited, Telix Pharmaceuticals Limited, Mesoblast Limited, Clinuvel Pharmaceuticals Limited, Immutep Ltd, Opthea Limited: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Peak Processing Limitedbase PKP.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Telix Pharmaceuticals Limited TLX.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Mesoblast Limited MSB.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Clinuvel Pharmaceuticals Limited CUV.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Immutep Ltd IMMP · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Opthea Limited OPT.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Incannex Healthcare Inc. IXHL · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Propanc Biopharma, Inc. PPCB · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | —— | $3.8 BAug 1, 2026 · Market data1st of 7 | $169 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 7 | $538 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 7 | $56 MAug 1, 2026 · Market data5th of 7 | $277 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 7 | $32 MOct 30, 2026 · Market data6th of 7 | $13 MOct 29, 2026 · Market data7th of 7 | $169 M7 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $804 MFY2025 · SEC1st of 4 | $17 MFY2025 · SEC3rd of 4 | $64 MFY2026 · SEC2nd of 4 | $7 MFY2025 · SEC4th of 4 | —— | —— | —— | $41 M4 ranked |
| Net income (Higher is better) | —— | $-7 MFY2025 · SEC2nd of 7 | $-102 MFY2025 · SEC6th of 7 | $23 MFY2026 · SEC1st of 7 | $-40 MFY2025 · SEC5th of 7 | $-163 MFY2025 · SEC7th of 7 | $-19 MFY2026 · SEC4th of 7 | $-19 MFY2026 · SEC3rd of 7 | $-19 M7 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +55.5%FY2025 · SEC2nd of 486th78th | +191.5%FY2025 · SEC1st of 496th97th | +5.2%FY2026 · SEC4th of 438th41st | +30.2%FY2025 · SEC3rd of 477th66th | ———— | ———— | ———— | +42.8%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +93.5%FY2025 · SEC1st of 395th86th | +19.0%FY2025 · SEC2nd of 371st41st | ———— | +10.9%FY2025 · SEC3rd of 356th32nd | ———— | ———— | ———— | +19.0%3 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | 0.0%FY2026 · SEConly one with it37th— | ———— | ———— | ———— | ———— | 0.0%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 53.0%FY2025 · SEC3rd of 340th— | 70.2%FY2025 · SEC2nd of 368th— | 82.9%FY2026 · SEC1st of 384th— | ———— | ———— | ———— | ———— | 70.2%3 ranked |
| Operating margin (Higher is better) | ———— | 3.7%FY2025 · SEC2nd of 263rd— | ———— | 43.4%FY2026 · SEC1st of 298th— | ———— | ———— | ———— | ———— | 23.6%2 ranked |
| Net margin (Higher is better) | ———— | -0.9%FY2025 · SEC2nd of 459th54th | -593.8%FY2025 · SEC3rd of 44th12th | 36.0%FY2026 · SEC1st of 497th96th | -594.8%FY2025 · SEC4th of 44th4th | ———— | ———— | ———— | -297.4%4 ranked |
| Free cash flow margin (Higher is better) | ———— | -5.3%FY2025 · SEC2nd of 444th35th | -294.4%FY2025 · SEC3rd of 411th15th | 18.4%FY2026 · SEC1st of 486th85th | -601.2%FY2025 · SEC4th of 44th5th | ———— | ———— | ———— | -149.9%4 ranked |
| Return on equity (Higher is better) | ———— | -1.9%FY2025 · SEC2nd of 671st68th | -18.9%FY2025 · SEC3rd of 661st48th | 13.4%FY2026 · SEC1st of 685th88th | -36.2%FY2025 · SEC4th of 651st42nd | ———— | -47.8%FY2026 · SEC5th of 644th38th | -161.8%FY2026 · SEC6th of 615th2nd | -27.6%6 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | 4.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | 8.4׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | —— |
| Price to book (Better neither way: ranked highest first) | ———— | 9.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | 0.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 0.5×price Oct 30, 2026 · Market data2nd of 27th— | 1.4×price Oct 29, 2026 · Market data1st of 228th— | 0.9×2 ranked |
| Free cash flow yield (Higher is better) | ———— | -1.1%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | -71.8%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | -39.8%price Oct 30, 2026 · Market data1st of 222nd— | -42.5%price Oct 29, 2026 · Market data2nd of 221st— | -41.1%2 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.9×FY2025 · SEC2nd of 275th— | 0.1×FY2025 · SEC1st of 221st— | ———— | ———— | ———— | ———— | ———— | 0.5×2 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -42.3×FY2026 · SEConly one with it23rd— | -42.3×— |
| Piotroski F-score (Higher is better) | —— | —— | 5 of 9FY2025 · SEConly one with it | —— | —— | —— | —— | —— | 5.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 6 of 10FY2025 · Scorecard2nd of 7 | 6 of 14FY2025 · Scorecard3rd of 7 | 9 of 11FY2026 · Scorecard1st of 7 | 3 of 12FY2025 · Scorecard4th of 7 | 0 of 7FY2025 · Scorecard7th of 7 | 3 of 12FY2026 · Scorecard4th of 7 | 2 of 12FY2026 · Scorecard6th of 7 | 25% passed7 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | —— | —— | 1 of 4FY2026 · Scorecard1st of 2 | 1 of 4FY2026 · Scorecard1st of 2 | 25% passed2 ranked |
| Growth checks (Higher is better) | —— | 3 of 4FY2025 · Scorecard1st of 7 | 3 of 6FY2025 · Scorecard2nd of 7 | 1 of 2FY2026 · Scorecard2nd of 7 | 2 of 6FY2025 · Scorecard4th of 7 | 0 of 2FY2025 · Scorecard5th of 7 | 0 of 2FY2026 · Scorecard5th of 7 | 0 of 2FY2026 · Scorecard5th of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | —— | 2 of 4FY2025 · Scorecard2nd of 7 | 0 of 3FY2025 · Scorecard3rd of 7 | 2 of 3FY2026 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard3rd of 7 | 0 of 2FY2025 · Scorecard3rd of 7 | 0 of 2FY2026 · Scorecard3rd of 7 | 0 of 3FY2026 · Scorecard3rd of 7 | 0% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 2FY2025 · Scorecard3rd of 7 | 3 of 4FY2025 · Scorecard2nd of 7 | 2 of 2FY2026 · Scorecard1st of 7 | 1 of 2FY2025 · Scorecard3rd of 7 | 0 of 2FY2025 · Scorecard7th of 7 | 1 of 2FY2026 · Scorecard3rd of 7 | 1 of 3FY2026 · Scorecard6th of 7 | 50% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecard3rd of 5 | 4 of 4FY2026 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 0 of 1FY2025 · Scorecard3rd of 5 | 1 of 2FY2026 · Scorecard2nd of 5 | —— | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 1.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | —— | —— | 1.1%2026-Q2 · 13F4th of 4 | —— | 4.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 1.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 1.4%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | —— | —— | 252026-Q2 · 13F2nd of 4 | —— | 172026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | 52026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | 214 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | -7.2 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | —— | -7.2 pp— |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 29.0%FY2026 · SEConly one with it98th— | ———— | 29.0%— |
| Dividend payout (Better neither way: ranked highest first) | ———— | ———— | ———— | 7.2%FY2026 · SEConly one with it17th— | ———— | ———— | ———— | ———— | 7.2%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Peak Processing Limited: How market caps are worked out; Telix Pharmaceuticals Limited: How market caps are worked out; Mesoblast Limited: How market caps are worked out; Clinuvel Pharmaceuticals Limited: How market caps are worked out; Immutep Ltd: How market caps are worked out; Opthea Limited: How market caps are worked out; Incannex Healthcare Inc.: How market caps are worked out; Propanc Biopharma, Inc.: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Peak Processing Limited | — | — | — |
| Telix Pharmaceuticals Limited | 3.7%FY2025 | 63rd percentile in Healthcaremedian -7.8%, 678 companies | — |
| Mesoblast Limited | — | — | — |
| Clinuvel Pharmaceuticals Limited | 43.4%FY2026 | 98th percentile in Healthcaremedian -7.8%, 678 companies | — |
| Immutep Ltd | — | — | — |
| Opthea Limited | — | — | — |
| Incannex Healthcare Inc. | — | — | — |
| Propanc Biopharma, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Peak Processing Limited | Telix Pharmaceuticals Limited | Mesoblast Limited | Clinuvel Pharmaceuticals Limited | Immutep Ltd | Opthea Limited | Incannex Healthcare Inc. | Propanc Biopharma, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2026 | — | — | — | $64 MSEC | — | — | — | — |
| 2025 | — | $804 MSEC1st | $17 MSEC3rd | $61 MSEC2nd | $7 MSEC4th | — | $0 MSEC5th | — |
| 2024 | — | $517 MSEC1st | $6 MSEC3rd | $58 MSEC2nd | $5 MSEC4th | $0 MSEC5th | $0 MSEC6th | — |
| 2023 | — | $334 MSEC1st | $8 MSEC2nd | — | $4 MSEC3rd | $0 MSEC4th | — | — |
| 2022 | — | $111 MSEC1st | $10 MSEC2nd | — | $5 MSEC3rd | $0 MSEC4th | — | — |
| 2021 | — | — | $7 MSEC1st | — | $3 MSEC2nd | $0 MSEC4th | $2 MSEC3rd | — |
| 2020 | — | — | $32 MSEC1st | — | $11 MSEC2nd | $0 MSEC4th | $1 MSEC3rd | — |
| 2019 | — | — | $17 MSEC1st | — | $5 MSEC2nd | $0 MSEC3rd | — | — |
| 2018 | — | — | $17 MSEC1st | — | $6 MSEC2nd | — | — | — |
| 2017 | — | — | $2 MSEC2nd | — | $3 MSEC1st | — | — | — |
| 2016 | — | — | $43 MSEC1st | — | $1 MSEC2nd | — | — | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Peak Processing Limited#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Telix Pharmaceuticals LimitedTLX.AX · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $3.8 B (Aug 1, 2026) · revenue $804 M (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Mesoblast LimitedMSB.AX · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $169 M (last known, Jan 5, 2024) · revenue $17 M (year to June 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Clinuvel Pharmaceuticals LimitedCUV.AX · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $538 M (last known, Jan 5, 2024) · revenue $64 M (year to June 2026)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Immutep LtdIMMP · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $56 M (Aug 1, 2026) · revenue $7 M (year to June 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Opthea LimitedOPT.AX · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $277 M (last known, Jan 5, 2024)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Incannex Healthcare Inc.IXHL · 🇦🇺 AustraliaSame sector: Healthcare (Pharmaceutical) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $32 M (Oct 30, 2026)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Propanc Biopharma, Inc.PPCB · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $13 M (Oct 29, 2026)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Kazia Therapeutics LimitedKZIA · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $154 M (Aug 1, 2026) · revenue $0 M (year to June 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Radiopharm Theranostics LimitedRAD.AX · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $23 M (last known, Jan 5, 2024) · revenue $4 M (year to June 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Alterity Therapeutics LimitedATHE · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $87 M (Aug 1, 2026)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Immuron LtdIMRN · 🇦🇺 AustraliaSame sector: Healthcare (Biotechnology) · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $9 M (Aug 1, 2026) · revenue $5 M (year to June 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
- Anteris Technologies Global Corp.AVR · 🇦🇺 AustraliaSame sector: Healthcare · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $564 M (Oct 27, 2026) · revenue $2 M (year to December 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.